Accessible Gene Therapy for Liver Diseases

HydroGene has developed a non-viral DNA delivery platform to create accessible gene therapy for all liver diseases. Our technology solves the limitations of AAV-based gene therapy approaches (cost, toxicity, lack of redosing). Achieving large DNA delivery also allows for mutation agnostic correction, addressing the limitations of gene editing approaches.

HydroGene has validated the technology in large animal models in preparation for clinical translation. Our initial focus is on achieving cures for rare genetic liver diseases before expanding into common disorders.